Search results for: Kathleen I. Pritchard

Items from 1 to 20 out of 84 results

article

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

John F. R. Robertson, Zefei Jiang, Angelo Leo, Shinji Ohno, more

Breast Cancer > 2019 > 26 > 6 > 703-711

Background Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC). Methods Meta-analysis of randomized controlled trials (RCTs) evaluating fulvestrant 500 mg in postmenopausal hormone receptor-positive ABC, to evaluate differences in clinical benefit rate (CBR; proportion...

article

Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis

Jacques Raphael, Danielle Desautels, Kathleen I. Pritchard, Ekaterina Petkova, more

European Journal of Cancer > 2018 > 91 > C > 38-46

Phosphoinositide 3-kinase (PI3K) inhibitors may overcome drug resistance and improve advanced breast cancer (ABC) outcomes. We conducted a systematic review and meta-analysis to assess the efficacy and safety of adding a PI3K inhibitor to the standard of care (SOC) treatment in ABC. The electronic databases Ovid, PubMed, Cochrane Central Register of Controlled Trials and Embase, were searched for...

article

Extended adjuvant therapy: the role of subset analyses

Kathleen I Pritchard

The Lancet Oncology > 2017 > 18 > 11 > 1431-1433

article

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27

Allan Lipton, Judith‐Anne W. Chapman, Kim Leitzel, Ashwani Garg, more

Cancer > 123 > 13 > 2444 - 2451

BACKGROUND Breast cancer patients in the MA.27 trial had similar outcomes with steroidal aromatase inhibitor (AI) exemestane and nonsteroidal anastrozole. AIs increase the risk of osteoporosis. This study examined the effects of self‐reported osteoporosis and osteoporosis therapy (OPT) on outcomes. METHODS The MA.27 phase 3 adjuvant trial enrolled 7576 postmenopausal women. The primary outcome...

article

Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32

Ana Elisa Lohmann, Mira F. Liebman, William Brien, Wendy R. Parulekar, more

Breast Cancer Research and Treatment > 2017 > 164 > 2 > 371-378

Background Metformin is associated with low levels of vitamin B12 (VitB12) in patients with diabetes. The CCTG/MA.32 trial investigates the effects of metformin vs placebo on breast cancer (BC) outcomes in non-diabetic high-risk BC patients. We analyzed VitB12 at baseline and after 6 months of metformin (versus placebo) in the first 492 patients with paired blood samples. Methods VitB12 was analyzed...

article

Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?

Punam Rana, Kathleen I. Pritchard, Robert Kerbel

European Journal of Cancer > 2017 > 70 > C > 143-145

article

Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence

Danielle N. Desautels, Phillip S. Blanchette, Kathleen I. Pritchard

European Journal of Cancer > 2016 > 68 > C > 176-178

article

The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?

Katarzyna J. Jerzak, Kathleen I. Pritchard

European Journal of Cancer > 2016 > 68 > C > 173-175

chapter

Guidelines, Consensus Conferences and Overviews (Meta-analysis)

Kathleen I. Pritchard

Cancer Treatment and Research > Adjuvant Therapy for Breast Cancer > Basics > 63-76

In the practice of oncology, and even in sub-specialties such as the care of women with breast cancer, it can be challenging and sometimes overwhelming to keep up to date with the latest discoveries and publications. In the past few years, the review article [1, 2] was the standard vehicle for keeping up to date for most clinicians. Review articles of this type, while often excellent summations of...

article

COGNITIVE SEQUELAE OF ADJUVANT ENDOCRINE THERAPY FOR THE TREATMENT OF BREAST CANCER IN OLDER WOMEN: A FEASIBILITY STUDY

Emily A. Underwood, Katarzyna J. Jerzak, Kathleen I. Pritchard, Mary C. Tierney

Alzheimer's & Dementia > 2016 > 12 > 7(S) > P770

article

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

Kathrin Strasser-Weippl, Nora Horick, Ian E. Smith, Joyce O'Shaughnessy, more

European Journal of Cancer > 2016 > 56 > C > 85-92

In resource-constrained environments many patients with human epidermal growth factor receptor 2 (HER2)+ early breast cancer are currently not offered adjuvant anti-HER2 therapy. For patients who might be able to receive the tyrosine kinase inhibitor (TKI) lapatinib (e.g. after patent expiration), it is important to identify subgroups of patients for whom anti-HER2 TKI therapy could be beneficial...

chapter

Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings

Shelly S. Lo, Kathleen I. Pritchard, Patricia Robinson, Kathy S. Albain

Cancer Treatment and Research > Hormone Receptors in Breast Cancer > 1-29

article

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study

Dennis C. Sgroi, Judy-Anne W. Chapman, T. Badovinac-Crnjevic, Elizabeth Zarella, more

Breast Cancer Research > 2016 > 18 > 1 > 1-7

Background Biomarkers that can be used to accurately assess the residual risk of disease recurrence in women with hormone receptor–positive breast cancer are clinically valuable. We evaluated the prognostic value of the Breast Cancer Index (BCI), a continuous risk index based on a combination of HOXB13:IL17BR and molecular grade index, in women with early breast cancer treated with either tamoxifen...

article

The effect of melatonin on sleep and quality of life in patients with advanced breast cancer

Pasquale F. Innominato, Andrew S. Lim, Oxana Palesh, Mark Clemons, more

Supportive Care in Cancer > 2016 > 24 > 3 > 1097-1105

Background Fatigue and sleep problems are prevalent in cancer patients and can be associated with disruption of circadian rhythmicity. In this prospective phase II trial, we sought to assess the effect of melatonin on circadian biomarkers, sleep, and quality of life in breast cancer patients. Methods Thirty-two patients with metastatic breast cancer, receiving hormonal or trastuzumab therapy, took...

article

Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14

Judith-Anne W. Chapman, Dennis C. Sgroi, Paul E. Goss, Elizabeth Zarella, more

Breast Cancer Research and Treatment > 2016 > 157 > 1 > 101-108

Recent ASCO/CAP guidelines focus on decision making associated with the presence/absence of continuous breast biomarkers. Statistical standardization (SS) is demonstrated as a method to evaluate the effects of continuous RT-PCR biomarker expression levels on breast cancer outcomes. MA.14 allocated 667 postmenopausal patients to tamoxifen based on locally determined ER/PR. Of 299 available patient...

article

Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies

Philip E. Lee, Mary C. Tierney, Wei Wu, Kathleen I. Pritchard, more

Breast Cancer Research and Treatment > 2016 > 158 > 3 > 407-420

Endocrine-based treatments are the mainstay of therapy for postmenopausal women with breast cancer; yet concern has been raised about potential adverse cognitive effects. We performed a systematic review of the published literature to evaluate whether endocrine-based treatments for breast cancer are associated with changes in cognitive domains and whether these effects are more pronounced with advanced...

article

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

Judith-Anne W. Chapman, Lois E. Shepherd, James N. Ingle, Hyman B. Muss, more

Breast Cancer Research and Treatment > 2016 > 156 > 2 > 343-349

Baseline patient and tumor characteristics differentially affected type of death in the MA.17 placebo-controlled letrozole trial where cardiovascular death was not separately identified. The MA.27 trial allowed competing risks analysis of breast cancer (BC), cardiovascular, and other type (OT) of death. MA.27 was a phase III adjuvant breast cancer trial of exemestane versus anastrozole. Effects of...

article

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Kathrin Strasser-Weippl, Nora Horick, Ian E Smith, Joyce O’Shaughnessy, more

Breast Cancer Research > 2015 > 17 > 1 > 1-7

Introduction Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described. Methods Using data from 1,260 patients randomized to placebo in the adjuvant TEACH trial, we report 10-year annual...

article

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

Frances M. Boyle, Ian E. Smith, Joyce O’Shaughnessy, Bent Ejlertsen, more

European Journal of Cancer > 2015 > 51 > 6 > 685-696

To evaluate health related quality of life (HRQOL) in TEACH, a phase III randomized placebo controlled trial of 12months of adjuvant lapatinib in HER2 positive (HER2+) early breast cancer which demonstrated marginal benefit in disease-free survival.Women on TEACH completed the Short Form 36-item health survey (version2; SF-36v2) at the baseline, six and 12months after therapy initiation and six monthly...

article

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

Maureen Elizabeth Trudeau, Judith-Anne W. Chapman, Baoqing Guo, Mark J. Clemons, more

SpringerPlus > 2015 > 4 > 1 > 1-11

This phase I/II neoadjuvant trial (ClinicalTrials.gov identifier NCT00066443) determined maximally-tolerated doses (MTD), dose-limiting toxicities, response-to-therapy, and explored the role of novel response biomarkers. MA.22 accrued T3N0, any N2 or N3, and T4 breast cancer patients. Treatment was 6 cycles of 3-weekly (Schedule A; N = 47) or 8 cycles of 2-weekly (Schedule B; N = 46) epirubicin/docetaxel...

Publication date

Set your own date range

INFONA - science communication portal

Search results for: Kathleen I. Pritchard

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis

Extended adjuvant therapy: the role of subset analyses

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27

Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32

Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?

Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence

The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?

Guidelines, Consensus Conferences and Overviews (Meta-analysis)

COGNITIVE SEQUELAE OF ADJUVANT ENDOCRINE THERAPY FOR THE TREATMENT OF BREAST CANCER IN OLDER WOMEN: A FEASIBILITY STUDY

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy

Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study

The effect of melatonin on sleep and quality of life in patients with advanced breast cancer

Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14

Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

Filter options

Publication date

Content availability

Publication type

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Kathleen I. Pritchard

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Publication type

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options